− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies planned by the end of 2024 – SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc.

-ABI-6250在临床前研究中显示出对丙型肝炎病毒的低纳摩尔效力和对NTCP的选择性抑制，预计每天一次给药-到2024年底计划进入临床研究-南旧金山，加利福尼亚州，10月02日，2023年（GLOBE NEWSWIRE）-Assembly Biosciences，Inc。

(Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-6250 to progress to IND-enabling studies. ABI-6250, an orally bioavailable small molecule entry inhibitor, is the first development candidate nominated by the company for the treatment of chronic hepatitis D virus (HDV) infection, and the second development candidate selected in 2023, following ABI-5366 for high-recurrence genital herpes.

（纳斯达克股票代码：ASMB）是一家开发针对严重病毒性疾病的创新抗病毒治疗药物的生物技术公司，今天宣布选择开发候选药物ABI-6250进行IND研究。ABI-6250是一种口服生物可利用的小分子进入抑制剂，是该公司提名用于治疗慢性丁型肝炎病毒（HDV）感染的第一个开发候选者，也是2023年选择的第二个开发候选者，紧随ABI-5366高复发生殖器疱疹。

“We’re pleased to nominate ABI-6250 as a development candidate targeting chronic HDV infection, the most severe form of viral hepatitis,” said William Delaney, PhD, chief scientific officer of Assembly Bio. “Current treatment options for HDV patients are limited and the only approved therapeutic requires daily injections.

组装生物首席科学官William Delaney博士说：“我们很高兴提名ABI-6250作为针对慢性HDV感染（最严重的病毒性肝炎）的发展候选者。”目前HDV患者的治疗方案有限，唯一批准的治疗方法需要每日注射。

We are excited to bring ABI-6250 forward into IND-enabling studies with the goal of providing the first oral chronic therapy for HDV patients.” HDV is a virus that infects liver cells in people who are also infected with hepatitis B virus (HBV). Patients with chronic HDV infection experience much higher rates of cirrhosis and liver cancer than those with chronic HBV infection only.

我们很高兴将ABI-6250推进IND启用研究，目的是为HDV患者提供首次口服慢性治疗。”HDV是一种感染乙型肝炎病毒（HBV）的人肝细胞的病毒。慢性HDV感染患者的肝硬化和肝癌发生率仅高于慢性HBV感染者。

In preclinical studies, ABI-6250 inhibited the interaction of HDV with sodium taurocholate co-transporting polypeptide (NTCP), the host receptor used by HBV/HDV to enter liver cells. Inhibiting viral entry by blocking NTCP is a clinically validated tar.

在临床前研究中，ABI-6250抑制HDV与牛磺胆酸钠共转运多肽（NTCP）的相互作用，NTCP是HBV/HDV进入肝细胞的宿主受体。通过阻断NTCP抑制病毒进入是临床验证的tar。